AUG 7, 2026 · PHASE 1/2 TRIAL
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov
This is a Phase 1/2 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
Reported
Estimated enrollment60
Phase 1 primary outcomeMaximum tolerated dose (MTD) and recommende…
Phase 2 primary outcomeFrequency of pathologic complete responses…